Brazilian Regulatory Has Expanded Registration For CytoSorbents' CytoSorb Blood Purification Technology To Treat Shock In Addition To Treating Cytokine Storm In Cardiac Surgery And Critical Illnesses
Portfolio Pulse from Benzinga Newsdesk
Brazil's regulatory body has expanded the registration for CytoSorbents' CytoSorb blood purification technology. The technology can now be used to treat shock, in addition to treating cytokine storm in cardiac surgery and critical illnesses.
August 31, 2023 | 11:26 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The expanded registration of CytoSorbents' CytoSorb technology in Brazil could potentially increase the company's market reach and revenue.
The expanded registration allows CytoSorbents to market their product for a wider range of medical conditions, potentially increasing their customer base and revenue. This is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100